Saturday, June 5, 2010

OncoLink at ASCO
OncoLink reporters provide in-depth coverage of scientific presentations from the 46^th Annual ASCO Meeting.

A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19 Presenter: G.D. Goss, MD Affiliation: The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada Background Platinum-based adjuvant chemotherapy in completely resected NSCLC had demonstrated a modest survival benefit of 5% at 5 years when this...
A randomized trial comparing endosonography followed by surgical staging versus surgical mediastinal staging alone in non-small cell lung cancer: The ASTER study Presenter: K.G. Tournoy, MD Affiliation: Ghent University Hospital, Ghent, Belgium Background Prognosis of patients with non-small cell lung cancer (NSCLC) depends heavily on nodal staging (Rusch, Journal of Thoracic Oncology 2007, 2:603-12)...
Contrasting effects of religious/spiritual support from religious communities versus medical teams on advanced cancer patient end-of-life care Presenter: T. A. Balboni Affiliation: Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA Background Previous studies have shown that religion/spiritual (R/S) concerns are important to the...
Effect of YOCAS yoga on sleep, fatigue, and quality of life: A URCC CCOP randomized, controlled clinical trial among 410 cancer survivors Presenter: K.M. Mustian Affiliation: University of Rochester Medical Center, Rochester, NY Background It is well known that fatigue and impaired sleep quality (SQ) are side effects often seen in cancer survivors, which can interfere with...
Glioblastoma (GBM) in elderly patients: A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ) Presentor: A. Malmstrom Affiliation: Unit of Advanced Palliative Home Care, Linköping, Sweden Background Glioblastoma Multiforme (GBM) is the most common primary malignant brain tumor, accounting for 40% of primary CNS Malignancies The...
Limited-stage diffuse large B-cell lymphoma (DLBCL) treated with abbreviated systemic therapy and consolidation radiotherapy: Involved field radiotherapy (IFRT) versus involved nodal radiotherapy (INRT≤5cm) Presenter: B. A. Campbell Affiliation: British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma (NHL), and...
Long-term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer Presenter: V. Westeel, MD, on behalf of the Intergroupe Francophone de Cancerologie Thoracique Background This is an update of a previously reported French Phase III randomized trial (DePierre, JCO 2002) comparing neo-adjuvant chemotherapy...
Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG1 randomized phase IV trial Presenter: E. Thiel Affiliation: Department of Hematology, Charite Campus Benjamin Franklin, Berlin, Germany Background Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma (NHL). It is restricted...
Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study Presenter: T. Cloughesy for the BRAIN Investigators Affiliations: University of California, Los Angeles Neuro-Oncology Program, Los Angeles, CA Background Glioblastoma Multiforme (GBM) is the most common primary malignant brain tumor...